Sanctura Once-Daily NDA Touts “Landmark Tolerability”
This article was originally published in The Pink Sheet Daily
Indevus will position the XR version of its incontinence therapy based on its low incidence of dry mouth.
You may also be interested in...
Indevus reports Phase III trial results confirming earlier data demonstrating the efficacy of the once-daily overactive bladder treatment.
Co-promotion agreement leaves the door open for P&G and Novartis to solicit FDA for approval of Enablex as OTC. Deal brings expanded sales force in a crowded market.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.